Expertise in
3
conditions

Dr. Vibha T. Thomas

Texas Oncology PA
Plano, TX
Expertise in
3
conditions
Specialties:Oncology | Hematology Oncology
Accepting New Patients
Offers Telehealth
Expertise in
3
conditions
OverviewInsuranceLocationsClinical Research

Overview

Vibha Thomas is an Oncologist and a Hematologist Oncology provider in Plano, Texas. Dr. Thomas is highly rated in 3 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Multiple Myeloma. Dr. Thomas is currently accepting new patients.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in CO
Hospital Affiliations
Sana Healthcare Carrollton D/b/a Carrollton Regional Medical Center
Texas Health Presbyterian Hospital Flower Mound
Medical City Lewisville
Texas Health Presbyterian Hospital Plano
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Moda Health
  •  Friday Health
  •  Scott and White Health
  •  Oscar
  •  UnitedHealthcare
View 1 More Insurance +

Locations

TEXAS ONCOLOGY PA
3705 W 15th St, Plano, TX 75075
972-867-3577
Other Locations
TEXAS ONCOLOGY PA
7777 Forest Ln, Suite C707, Dallas, TX 75230
972-566-3000
TEXAS ONCOLOGY PA
4370 Medical Arts Dr, Suite 100, Flower Mound, TX 75028
972-537-4100
TEXAS ONCOLOGY PA
3410 Worth St, Suite 730, Dallas, TX 75246
214-370-1000
TEXAS ONCOLOGY PA
2026 S Jackson St, Jacksonville, TX 75766
903-586-2456
TEXAS ONCOLOGY PA
7848 Gateway Blvd E, El Paso, TX 79915
915-599-1313

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2024
Intervention Type: Device
Study Phase: Not Applicable
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
Breast Cancer Index (BCI) Registry
Breast Cancer Index (BCI) Registry
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Diagnostic test
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Enrollment Status: Terminated
Publish Date: March 13, 2023
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

3 Total Publications

Myelodysplastic Syndrome Associated With Auto-Immune Inflammatory Disease in VEXAS Syndrome.
Myelodysplastic Syndrome Associated With Auto-Immune Inflammatory Disease in VEXAS Syndrome.
Journal: Journal of hematology
Published: October 27, 2021
Similar Doctors
Expertise in
30
conditions
Dr. Farrukh T. Awan
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Farrukh T. Awan
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (14.7 mi)
214-633-5555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Farrukh Awan is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Awan is highly rated in 30 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Awan is currently accepting new patients.

Expertise in
22
conditions
Dr. Larry D. Anderson
Oncology | Hematology | Hematology Oncology
Expertise in
22
conditions
Dr. Larry D. Anderson
Oncology | Hematology | Hematology Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (14.6 mi)
214-645-2700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Anderson is an Oncologist and a Hematologist in Dallas, Texas. Dr. Anderson is highly rated in 22 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Anderson is currently accepting new patients.

Expertise in
8
conditions
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology
Expertise in
8
conditions
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (14.6 mi)
214-645-0624
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Brugarolas is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Brugarolas is highly rated in 8 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy. Dr. Brugarolas is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile